Yüklüyor......
Patients with Terminal Interstitial Pneumonia Require Comparable or More Palliative Pharmacotherapy for Refractory Dyspnea than Patients with Terminal Lung Cancer
Background: Dyspnea is a severe symptom of terminal-stage interstitial pneumonia (IP). We commonly use continuous morphine or midazolam for terminal refractory dyspnea. Objective: We aimed to determine whether there is a difference in the use of continuous morphine and midazolam for terminal dyspnea...
Kaydedildi:
| Yayımlandı: | Palliat Med Rep |
|---|---|
| Asıl Yazarlar: | , , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Mary Ann Liebert, Inc., publishers
2021
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8244508/ https://ncbi.nlm.nih.gov/pubmed/34223519 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1089/pmr.2021.0010 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|